A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Intravenous MR11A8 in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome
Phase of Trial: Phase III
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Adult respiratory distress syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Maruishi Pharmaceutical
- 11 Dec 2017 According to a Faron Pharmaceuticals media release, Faron's Japanese partner Maruishi expects results of this trial in 2018.
- 26 Oct 2017 Planned End Date changed from 30 Jun 2018 to 31 Dec 2018.
- 06 Sep 2017 According to a Faron Pharmaceuticals media release, company anticipates completion of patient recruitment during H1 2018.